Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19) (ISCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04383730
Recruitment Status : Recruiting
First Posted : May 12, 2020
Last Update Posted : July 7, 2020
Sponsor:
Collaborators:
Hospital Clínico Universitario de Valencia
University Hospital Schleswig-Holstein
Groupe Hospitalier Pitie-Salpetriere
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand

Brief Summary:

The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation.

The authors therefore designed the "Inhaled Sedation for COVID-19-related ARDS" (ISCA) non-interventional, observational, multicenter study of data collected from the patients' medical records in order to:

  1. assess the efficacy of inhaled sedation in improving a composite outcome of mortality and time off the ventilator at 28 days in patients with COVID-19-related ARDS, in comparison to a control group receiving intravenous sedation (primary objective),
  2. investigate the effects of inhaled sedation, compared to intravenous sedation, on lung function as assessed by gas exchange and physiologic measures in patients with COVID-19-related ARDS (secondary objective),
  3. report sedation practice patterns in critically ill patients during the COVID-19 pandemics (secondary objective).

Condition or disease Intervention/treatment
Critically Illness Sedation Invasive Mechanical Ventilation Acute Respiratory Distress Syndrome Drug: Intravenous sedation Drug: Inhaled sedation

Detailed Description:

The acute respiratory distress syndrome (ARDS) is the most severe and lethal complication of COVID-19, and healthcare resource utilizations are currently being heavily challenged in most countries worldwide, with a high risk that some intensive care resources, such as the number of ventilators to allow management all patients, may be insufficient to face the current surge in ARDS cases. There is, therefore, an urgent need to evaluate candidate therapies that may impact clinical outcomes in patients with COVID-19-related ARDS and potentially be relevant to current public health issues, in accordance with the international efforts by the World Health Organization (WHO) (Global research on coronavirus disease) and most international public health organizations. Beyond the current efforts to find specific antiviral therapies or vaccines, improving supportive care and treatment options for patients with COVID-19-related ARDS, in accordance with up-to-date guidelines on the management of critically ill patients with COVID-19 (Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019; The Australian and New Zealand Intensive Care Society (ANZICS) COVID-19 Guidelines; Recommandations d'experts SRLF-SFAR-SFMU-GFRUP-SPILF sur la prise en charge en réanimation des patients en période d'épidémie à SARS-CoV2), is of major importance.

Indeed, given the number of intensive care unit (ICU) patients for whom the question of sedation applies during the current COVID-19 outbreak, any sedation practice that would be associated with improved clinical outcomes could have significant economic and public health implications. In this perspective, the rationale supporting inhaled sedation with halogenated agents (such as isoflurane or sevoflurane) as a way to improve lung function, to decrease the inflammatory response, and to possibly improve patient outcome is strong.

The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation. The authors, therefore, designed the "Inhaled Sedation for COVID-19-related ARDS" (ISCA) non-interventional, observational, multicenter study of data collected from the patients' medical records in order to :

  1. assess the efficacy of inhaled sedation in improving a composite outcome of mortality and time off the ventilator at 28 days in patients with COVID-19-related ARDS, in comparison to a control group receiving intravenous sedation (primary objective),
  2. investigate the effects of inhaled sedation, compared to intravenous sedation, on lung function as assessed by gas exchange and physiologic measures in patients with COVID-19-related ARDS (secondary objective),
  3. report sedation practice patterns in critically ill patients during the COVID-19 pandemics (secondary objective).

This study will be performed in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
Actual Study Start Date : June 26, 2020
Estimated Primary Completion Date : November 30, 2020
Estimated Study Completion Date : December 31, 2020


Group/Cohort Intervention/treatment
Usual practice of intravenous sedation
The choice of the intravenous sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center
Drug: Intravenous sedation
Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices

Usual practice of inhaled sedation
The choice of the inhaled sedative agent, including the type of and dosing of the agent, will be as per the treating clinicians at each center.
Drug: Inhaled sedation
Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices




Primary Outcome Measures :
  1. Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event [ Time Frame: Day 28 after inclusion ]
    Ventilator-free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after intubation, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a patient returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28. A period of assisted breathing lasting less than 24 hours and for the purpose of a surgical procedure will not count against the VFD calculation. If a patient was receiving assisted breathing at day 27 or died prior to day 28, VFDs will be zero. Patients transferred to another hospital or other health care facility will be followed to day 28 to assess this endpoint.


Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: Days 7, 14, and 28 after inclusion ]
    All-cause mortality

  2. Ventilator-free days [ Time Frame: Days 7 and 14 after inclusion ]
    Ventilator-free days to days 7 and 14 are defined as the number of days from the time of initiating unassisted breathing to day 7 and 14 after intubation, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to days 7 and 14 If a patient returns to assisted breathing and subsequently achieves unassisted breathing to days 7 and 14 , VFDs will be counted from the end of the last period of assisted breathing to days 7 and 14. A period of assisted breathing lasting less than 24 hours and for the purpose of a surgical procedure will not count against the VFD calculation. If a patient was receiving assisted breathing at day 6 or 13 or died prior to days 7 and 14, respectively,VFDs to days 7 and 14 will be zero. Patients transferred to another hospital or other health care facility will be followed to days 7 and 14 to assess this endpoint.

  3. ICU-free days [ Time Frame: Day 28 after inclusion ]
    Number of days alive and not in the ICU from inclusion to day 28

  4. Duration of invasive mechanical ventilation [ Time Frame: Day 28 after inclusion ]
    Total duration of controlled mechanical ventilation to day 28

  5. Duration of controlled mechanical ventilation [ Time Frame: Day 28 after inclusion ]
    Total duration of controlled mechanical ventilation to day 28

  6. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    Arterial hypoxemia, as assessed by the partial pressure of arterial oxygen-to-fraction of inspired oxygen ratio (PaO2/FiO2)

  7. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    Partial pressure of arterial carbon dioxide (PaCO2)

  8. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    Inspiratory plateau pressure

  9. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    Driving pressure

  10. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    Mode of mechanical ventilation (assisted versus controlled)

  11. Physiological measures of lung function [ Time Frame: Days 1, 2, 3, 4, 5, 6, and 7 from inclusion ]
    If available, 100 ms occlusion pressure (P0.1), a marker of respiratory drive

  12. Development of complications [ Time Frame: Day 7 from inclusion ]
    Development of pneumothorax

  13. Development of complications [ Time Frame: Day 7 from inclusion ]
    Supraventricular tachycardia

  14. Development of complications [ Time Frame: Day 7 from inclusion ]
    New onset atrial fibrillation

  15. Duration of vasopressor use [ Time Frame: Day 28 after inclusion ]
    Total duration (in days) of vasopressor use

  16. Duration of renal replacement therapy [ Time Frame: Day 28 after inclusion ]
    Total duration (in days)of renal replacement therapy

  17. Duration (in days) of any adjuvant therapies [ Time Frame: Day 7 from inclusion ]
    Adjuvant therapies are defined as: prone position, recruitment maneuvers, inhaled nitric oxide, inhaled epoprostenol sodium, high frequency ventilation, ECMO, neuromuscular blockade

  18. Duration of continuous neuromuscular blockade [ Time Frame: Day 28 from inclusion ]
    Number of days with continuous neuromuscular blockade

  19. Type of sedation practices [ Time Frame: Day 28 from inclusion ]
    Sedation drug(s) used (name(s))

  20. Duration of sedation practices [ Time Frame: Day 28 from inclusion ]
    Number of days with sedation

  21. Modalities of sedation practices [ Time Frame: Day 28 from inclusion ]
    If inhaled sedation, device used to deliver it



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients admitted in ICUrequiring invasive mechanical ventilation and suspected or confirmed COVID19
Criteria

Inclusion Criteria:

  • Adult patients (18 years old),
  • Admitted to a participating ICU (or any other ICU-like setting that may be deployed as a result of the COVID-19 pandemics, such as in the operating room, post-anesthesia care unit, step-down unit or any COVID-19-specific unit set in response to the pandemics in a participating center),
  • Requiring invasive mechanical ventilation,
  • With suspected or confirmed COVID-19 on day 0.

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04383730


Contacts
Layout table for location contacts
Contact: Lise Laclautre +33 4 73 754963 promo_interne_drci@chu-clermontferrand.fr

Locations
Layout table for location information
France
CHU Recruiting
Clermont-Ferrand, France, 63000
Contact: Matthieu Jabaudon       mjabaudon@chu-clermontferrand.fr   
Centre Hospitalier Not yet recruiting
Dunkerque, France
Contact: Caroline Varillon         
Contact       caroline.varillon@ch-dunkerque.fr   
Pitié-Salpêtrière Hospital - APHP Not yet recruiting
Paris, France, 75013
Contact: Jean-Michel Constantin       jean-michel.constantin@aphp.fr   
CH Privé de la Loire Not yet recruiting
Saint-Étienne, France
Contact: Pierre Boucher       pierreboucher85@yahoo.fr   
Germany
University Medical Center Schleswig-Holstein Not yet recruiting
Kiel, Germany
Contact: Tobias Becher       tobias.becher@uksh.de   
Spain
Hospital Clínico Universitario de Valencia Not yet recruiting
Valencia, Spain
Contact: Rafael Badenes       rafaelbadenes@gmail.com   
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Hospital Clínico Universitario de Valencia
University Hospital Schleswig-Holstein
Groupe Hospitalier Pitie-Salpetriere
Investigators
Layout table for investigator information
Study Chair: Matthieu Jabaudon University Hospital, Clermont-Ferrand
Layout table for additonal information
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT04383730    
Other Study ID Numbers: ISCA Study
First Posted: May 12, 2020    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Clermont-Ferrand:
Mechanical ventilation
Acute Respiratory Distress Syndrome
Inhaled sedation
Intravenous sedation
Covid-19
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Syndrome
Disease
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Lung Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury